Hanmi Pharmaceutical Co., Ltd.’s in-house developed long-acting glucacon-like peptide-1 receptor agonist efpeglenatide has received the Ministry of Food and Drug Safety’s approval to begin a Phase III trial, moving closer to commercialization of the first one of several obesity pipeline projects it is focusing on as a next growth engine, the Hanmi Obesity Pipeline (HOP).
Hanmi’s GLP-1 Obesity Contender Gets Phase III Nod In Korea
Hanmi aims to commercialize its GLP-1 obesity treatment, the first one from its ambitious HOP project, within three years as it moves to Phase III in Korea.
